GOG 3003: A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of VTX-2337 (IND #78,416)… in Patients with Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Service: Trial Number:
121-12
Principal Investigator: Conducted at:
Long Beach Memorial, Orange Coast Memorial
Currently enrolling additional patients:
Yes

GOG 3003: A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of VTX-2337 (IND #78,416) in Combination with Pegylated Liposomal Doxorubicin (Doxil®) in Patients with Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer. The purpose of this study is to compare pegylated liposomal doxorubicin (PLD; a standard chemotherapy) to PLD in combination with VTX-2337 (a new type of drug that stimulates the immune system) to see if it helps cancer tumors stop growing or shrink, and if it helps women with epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer that has returned after treatment or did not respond to earlier treatment. It is being carried out by the Gynecologic Oncology Group (GOG) an organization dedicated to clinical research in the gield of gynecologic cancer. The GOG is partly funded by the federal government through the National Cancer Institute (NCI).

MemorialCare Research Center Contact Form

For further information about this study or to express your interest in this study, please fill out and submit this form.
Address
,
 
The email to associate with this registration.